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Abstract.  Substantial amounts of epidermal growth 
factor (EGF) are cleared from the circulation by hepa- 
tocytes via receptor-mediated endocytosis and subse- 
quently degraded within lysosomes. We have used a 
combined biochemical and morphological approach 
to examine the fate of the receptor after exposure to 
EGF. Polyclonal antibodies were prepared against the 
purified receptor and their specificity established by 
immunoprecipitation and immunoblotting tech- 
niques. The EGF receptor was then localized by im- 
munofluorescence and immunoperoxidase techniques 
and quantified on immunoblots. In untreated livers, 
EGF receptor was restricted to the sinusoidal and lat- 
eral surfaces of hepatocytes. 2-4 min after exposure of 
cells to EGF, the receptor was found in small vesicles 
(i.e., coated vesicles) as well as larger vesicles and tu- 
bules at the cell periphery. By 15 min the receptor was 
found in multivesicular endosomes located near bile 
canaliculi. Exposure of hepatocytes to EGF also re- 
sulted in a rapid loss of receptor protein from total 
liver homogenates and a decrease in its half-life from 
8.7 h in control livers to 2.5 h. This EGF-induced loss 
of receptors was not observed when lysosomal pro- 
teinases were inhibited by leupeptin or when endo- 
some/lysosome fusion was prevented by low tempera- 
ture (16°C).  In the presence of leupeptin, receptor 
could be detected in structures identified as lysosomes 
using acid-phosphatase cytochemistry. All these results 
suggested rapid internalization of EGF receptors in 
response to ligand and degradation within lysosomes. 
However, four times more ligand was degraded at 8 h 
than the number of high-affinity (Kd of 8-15 nM) 
EGF-binding sites lost, suggesting either (a) high-af- 
finity receptors were recycled, and/or (b) more than 
300,000 receptors were available for EGF uptake. We 
identified and characterized a latent pool of-300,000 
low-affinity receptors (Kd ~  200 nM) that could be 
separated on sucrose gradients from the plasma mem- 
brane pool of ~300,000 high-affinity receptors (Kd of 
8-15 nM). Despite the differences in their binding 
affinities, the high- and low-affinity receptors ap- 
peared to be structurally identical and were both 
EGF-dependent protein kinases. In addition, the dy- 
namics of the low-affinity receptors were consistent 
with a functional role in EGF uptake and delivery to 
lysosomes. 
ECEPTOa-mediated endocytosis is well-recognized  as a 
general mechanism used by many cells for uptake of 
biologically important molecules (reviewed in refer- 
ences 7 and 51). The fates of these ligands, once internalized, 
vary from degradation to intracellular storage to transport 
across the cell and subsequent release. The receptors also have 
diverse fates, some being re-utilized, others degraded, and a 
few released with their ligand. The principle cell in the liver, 
the parenchymal cell or hepatocyte, possesses many specific 
membrane receptors that mediate the internalization of dif- 
ferent  molecules from  the  circulation.  The  fates of these 
ligands and their receptors encompass most currently estab- 
lished fates in receptor-mediated endocytosis. Therefore, this 
cell type is particularly welt-suited for a comparative study of 
multiple ligand-receptor systems. 
We have been studying the endocytosis of asialoglycopro- 
reins (ASGPs),  ~ epidermal growth factor (EGF), and poly- 
~.;lhhreviations used in this paper: anti-EGF-R,  antibodies against EGF recep- 
meric immunoglobulin A by rat hepatocytes (18-20, 28, 29, 
56). These molecules are internalized via receptor-mediated 
processes occurring at the sinusoidal surface of hepatocytes. 
Two of the ligands (ASGP and EGF) are delivered to lyso- 
somes and degraded (2,  17,  20), but the third,  polymeric 
immunoglobulin A, is transported across the cell and exocy- 
tosed into the bile (46). While the receptors for ASGPs are re- 
utilized (50), membrane  secretory component,  the receptor 
for polymeric immunoglobulin A, is apparently transported 
and a 90-kD fragment secreted into the bile along with the 
ligand (Hoppe, C. A. and A. L. Hubbard, unpublished results). 
Evidence from studies of  cultured cells indicates that the EGF 
receptor is delivered to lysosomes and degraded together with 
ligand (6,  I4,  34,  52). However, we recently reported that 
more EGF was internalized and degraded by hepatocytes than 
for;  ASGP, asialoglycoproteins;  EGF,  epidermal  growth  factor; EGF-HRP. 
conjugate of EGF to horseradish peroxidase; MVE, multivesicular endosomes; 
WGA, wheat germ agglutinin. 
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inhibited (20), suggesting that EGF receptors were re-utilized. 
An alternative possibility was that additional or cryptic recep- 
tors were recruited for continued ligand internalization. 
In  this  report,  we  have  used  anti-receptor antibodies  to 
investigate the dynamics of the EGF receptor in more detail. 
We have found that EGF induces a redistribution of receptors 
from the cell surface through all endosomal compartments to 
lysosomes. Furthermore, the amount of total receptor protein 
decreases upon exposure to ligand,  indicating  that it  is de- 
graded. Finally, we have identified a large pool of low-affinity 
receptors that can be separated from the high-affinity recep- 
tors on  sucrose gradients  of subcellular  fractions.  The  size 
(~50%  of total receptor protein) and dynamics of this low- 
affinity pool are consistent with its functioning in the contin- 
ued endocytosis of EGF. 
Materials and Methods 
Materials 
CD Sprague-Dawley rats were purchased from Charles River Breeding Labo- 
ratories (Wilmington, MA). EGF was prepared from mouse submaxillary glands 
(Pel-Freeze  Biologicals,  Rogers, AR) as described by Savage and Cohen (44) 
and iodinated to specific  radioactivities of 2-6 x  107 cpm/p,g (25).  Affi-Gel  10 
was obtained from Pharmacia Inc. (Piscataway, N J); Sepharose 4B from Sigma 
Chemical Co. (St. Louis, MO); Trasylol from Mobay Chemical Corp. (Pittsburg, 
PA); antipain, leupeptin, and pepstatin were from Peninsula Laboratories, Inc. 
(Belmont, CA); complete Freund's adjuvant and incomplete Freund's adjuvant 
were from Difco Laboratories Inc. (Detroit, MI); rhodaminated goat anti-rabbit 
lgG was from Kirkegaard & Perry Laboratories, inc. (Gaithersburg, MD): and 
horseradish peroxidase-conjugated  sheep anti-rabbit  Fab was from  Pasteur 
Productions (Marnes La Coquette,  France).  Protein  A  (Pharmacia  Inc.) was 
iodinated using the chloromine T  method (25) with resulting specific  radioac- 
tivities  of 3-5  ×  107  cpm/ug.  Adenosine-5'-["/-32p]triphosphate (10-25  Ci/ 
mmol) was from ICN Pharmaceuticals,  Inc. (Irvine, CA).  All  other reagents 
and compounds were of the highest purity available and were purchased from 
commercial sources or from sources reported in earlier publications (20,  30, 
42). 
Purification of EGF Receptor and Preparation of 
Antibodies to the Receptor 
EGF-Affi-Gel  l0  (0.7-1.0  mg/ml of packed  bed  volume) was prepared and 
EGF receptor purified from rat liver by affinity chromatography as described 
by Cohen et al. (11).  Aliquots ofeluted material were analyzed by SDS PAGE. 
Fractions containing bands at  180 and  165 kD in >95% purity (as assessed by 
Coomassie Blue staining) were pooled and used as immunogen. Receptor yields 
were 0.1-0.3 mg/100 g of liver tissue. 
A New Zealand white female rabbit (Bunnyville Farms, Littletown, PA) was 
immunized intradermally at multiple sites with 100 ~g of purified EGF receptor 
in Triton  X-100 emulsified in Freund's complete adjuvant.  After boosting 2 
wk later with 50 tLg of purified receptor in incomplete adjuvant, the rabbit was 
bled  and  the  serum  screened  for antibody  by  microtiter  and  immunoblot 
techniques (42).  Antibody titer remained constant for up to 10 mo. 
Antibodies against the EGF receptor (anti-EGF-R) were further purified from 
serum by ion-exchange chromatography (58) or by affinity chromatography 
using purified receptor coupled to Sepharose 4B (36) and isotonic glycine-HCl 
(pH 3) elution. Ion-exchange chromatography yielded  15-20 mg lgG per 3 ml 
of serum while 0.2-0.3 mg of affinity-purified anti-receptor lgG was recovered 
per milliliter of serum applied to an EGF-receptor-Sepharose column. 
Isolated Perfused Liver System 
Livers from  rats (150-250  g)  fasted  for 24  h  were surgically removed and 
perfused in a recirculating system as previously described (17,  19). Livers were 
perfused at  16"C or at 37"C in the presence or absence of leupeptin (0.4 mM) 
for 15 min before addition of EGF (20 nM), and the rates and extents of ~2~I- 
EGF internalization  and degradation determined from the amounts of acid- 
soluble and insoluble radioactivity in the perfusate and liver (20). To investigate 
the  effects  of EGF  on  the  cellular  distribution  of its  receptor,  livers  were 
perfused with  10 ug of EGF at 4"C. washed free of unbound ligand,  and then 
warmed to 37°C for 4 or 15 min, or perfused with 15 ug of EGF for 15 min at 
37"C.  Livers  were  then  fixed  by  perfusion  and  the  receptors  localized  by 
immunofluorescence and/or immunoperoxidase cytochemistry (see below). We 
examined the effects  of EGF on receptor degradation by perfusing livers with 
0.5  mM cycloheximide (to inhibit new receptor synthesis) in the absence or 
presence of EGF at 37"C for 1-8 h. Biopsies were taken before and at selected 
times after ligand addition, liver homogenates prepared, and the EGF-binding 
sites and receptor protein quantitated as described below. 
Subcellular Fractionation of Liver Homogenates 
Livers not previously exposed to EGF (called  naive livers) or perfused with 15 
ug of j2~I-EGF for 2 h at 16"C were homogenized and the 12K and microsomal 
pellets prepared. These pellets were then resuspended and subfractionated on 
linear 1.06-1.20 g/cc or 1.1 I - 1.25 g/cc sucrose gradients as previously described 
(20).  Accessible  (- Brij  35) and total (+ Brij  35) EGF-binding activities were 
measured  (see  below)  and  relative  amounts of receptor  protein  present  in 
subeellular fractions and  in  fractions obtained  from sucrose gradients were 
determined using immunoblot techniques described below. 
Quantification of EGF Receptors 
EGF-Binding Activity. Accessible  (- Brij 35) and total (+ Brij 35) EGF binding 
activities were measured in vitro on aliquots of liver homogenates (1.5-2  mg 
protein), subeellular fractions (1-2 mg protein), and  fractions obtained from 
sucrose gradients as previously described (20).  Briefly, samples were incubated 
with 80  nM  t2~I-EGF (20-100,000  cpm/ng) for 60-90  min at 4°C,  and the 
EGF-receptor complex was precipitated  in  10% polyethylene glycol  and col- 
lected  on  Whatman  GF/C  filters  (Whatman  Inc., Clifton,  N J).  This ligand 
concentration was sufficient for saturating high-affinity receptors (see Fig.  1 in 
reference 20).  For Scatchard analyses,  100 ul (0.2-0.4  mg protein) of sucrose 
gradient fractions were incubated with 5-500 nM  ~251-EGF in the presence of 
0.3%  Brij  35.  We have shown that Brij  35  is the most effective  detergent for 
measuring total  functional  or  high-affinity EGF receptors.  Other detergents 
(Triton  X-100, digitonin,  2-deoxycholate,  Lubrol WX, and  3-[(3-cholamido- 
propyl)dimethyl-ammonial]-l-propane-sulfonate) dramatically  reduced  EGF- 
binding in liver homogenates and were therefore inappropriate for measuring 
receptors (see Fig. 3 in reference 20).  Brij 35 had no effect on receptor number 
in homogenates of freshly isolated livers and changed receptor affinity slightly 
(from a Kd of 8-15  nM to a Kd of 24 riM).  The total number of high-affinity 
receptors  was determined  from  the  highest  value  of EGF-binding  activity 
measured in the presence of Brij 35. To ensure maximal EGF binding, several 
concentrations of Brij  35  were  used,  0.2-0.3%  (wt/wt) being sufficient for 
sucrose gradient fracti'ons and 0.5-0.8% (wt/wt) for homogenates or subcellular 
fractions. 
Receptor Protein on  lmmunoblots.  Aliquots of purified  receptor,  liver ho- 
mogenate, or sucrose gradient fractions were solubilized  in  1% SDS without 
dithiothreitol at 50"C for 10 min and the polypeptides separated on 7.5%  SDS 
polyacrylamide slab gels. The polypeptides were then electrophoretically trans- 
ferred to nitrocellulose (53) and the receptor detected as previously described 
(42),  using affinity-purified anti-EGF-R lgG followed by ~251-1abeled protein A. 
The nitrocellulose was exposed to x-ray film at  -70°C  with an  intensifying 
screen.  The relative amount of receptor protein  present was determined  by 
scanning the developed  film and integrating the area under both peaks (170 
kD and  155  kD)  using a  Hewlett-Packard  Integrator (Hewlett-Packard  Co., 
Palo Alto. CA) connected to a scanning densitometer (Hoefer Scientific  Instru- 
ments, San Francisco, CA). Linearity of this quantitation was established using 
standard curves of 4-5 different amounts of liver homogenate that covered a 
10-fold range of receptor protein. Since it was difficult to standardize the many 
variables in this procedure, standard curves were recalculated for each gel to 
ensure that the band densities were within the limits of linearity. 
Immunofluorescence and 
Immunoperoxidase  Cytochemistry 
Livers were fixed by perfusion with 2% paraformaldehyde/0.075 M lysine/0.01 
M sodium periodate/0.037  M sodium phosphate, pH 7.4, cut into small blocks 
and  fixed  an additional  1-6  h at room temperature.  Processing and indirect 
immunostaining of 0.5-urn frozen sections were performed as described (42) 
using affinity-purified anti-EGF-R IgG and rhodaminated goat anti-rabbit lgG. 
For co-localization  studies,  acid  phosphatase  histochemistry using cytidine 
monophosphate (CMP) as a  substrate (40) was done immediately before the 
antibody incubations. EGF receptors were visualized at the ultrastructural level 
using affinity-purified anti-EGF-R lgG and a horseradish peroxidase conjugate 
of sheep anti-rabbit Fab according to Brown and Farquhar (9). Acid phospha- 
tase was localized  at the ultrastructural level using CMP and cerium as described 
by Robinson and Karnovsky (41). 
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Immobilized Antibody 
Aliquots of liver homogenates and sucrose gradient fractions were solubilized 
in either buffer A (20 mM Hepes, pH 7.4, 2% Triton  X-100, 10% glycerol, 5 
mM  EGTA,  0.5  mM phenylmethylsulfonyl  fluoride,  2  mM  MgC12, 2  mM 
benzamidine,  10 KIU/ml Trasylol,  1 /ag/ml antipain,  1 #g/ml leupeptin, 0.5 
ug/ml pepstatin, and 0.02% NAN3) or buffer B (0.025 M NaPO,, pH 7.4, 0.5% 
Triton  X-100, 20 mM octylglucoside, 0.3 M NaCI, 10 KIU/ml Trasylol, 1 ug/ 
ml antipain,  1 ug/ml leupeptin, and 0.02% NAN3) and centrifuged for 90 min 
at  150,000 gay. The solubilized extract was incubated  with anti-receptor IgG- 
Sepharose  15-24  h at 4"C after  the  procedures  of Slieker and  Lane (48) or 
Hubbard  et al. (30) with minor modifications.  The beads were then washed 
and  the  bound  receptor  solubilized  in  4%  SDS/15  mM  dithiothreitol  and 
electrophoresed in polyacrylamide gels. 
Analytical Procedures 
Protein and Enzyme Assays. Protein  and enzyme markers  for plasma  mem- 
branes  (alkaline  phosphodiesterase)  and  lysosomes (/3-N-acetyl-glucosamini- 
dase) were assayed as described (20). 
Receptor Phosphorylation. Phosphorylation  of the  EGF receptor either  in 
purified  form  or in 0.5-2%  Triton  X-100-solubilized  liver homogenates  or 
sucrose gradient fractions was carried out in the presence of EGF as described 
by Rubin  and Earp (43) and analyzed on SDS polyacrylamide gels. Phospho- 
rylated receptor from 32P-labeled homogenates  was immunoprecipitated  with 
anti-EGF-R lgG-Sepharose following the procedures of Hubbard et al. (30). 
Lectin Labeling. J25I-Wheat  germ agglutinin (WGA) was applied to nitrocel- 
lulose blots ofimmunoprecipitated receptor according to the methods of Bartles 
and Hubbard (4). 
Results 
Preparation of  Antibodies against EGF Receptor 
Preparations of EGF receptor purified from rat liver by affin- 
ity  chromatography  routinely  yielded  two  major  protein 
bands of 180 and 165 kD when analyzed by SDS PAGE under 
reducing conditions (Fig.  1).2 The purified receptor retained 
its kinase activity as measured by autophosphorylation. How- 
ever, 32p incorporation was predominantly into the  180-kD 
band  (i.e.,  the  intact receptor), consistent with  reports that 
the  165-kD protein is a proteolytic fragment of the receptor 
and does not contain the phosphorylation site(s) (12,  57). 
Antibodies prepared against the  receptor recognized both 
SDS-denatured and Triton-solubilized forms of the molecule 
(Fig.  1). The antibody reacted with the SDS-denatured recep- 
tor only when reduction of  disulfides was omitted. When total 
liver  polypeptides  were  solubilized  and  separated  by  SDS 
PAGE,  then  transferred  onto  nitrocellulose,  the  antibody 
bound to only two polypeptides, whose apparent molecular 
weights (Mr of 170,000  and  155,000)  were identical to those 
of the nonreduced purified receptor (Fig.  1A). The abundant 
Coomassie Blue-staining protein(s) at Mr of 160,000-170,000 
did not represent the EGF receptor and were not recognized 
by our antibodies, since they resided in vesicles that could be 
separated from receptor-containing vesicles on  sucrose gra- 
dients (results  not  shown).  When  solubilized liver homoge- 
nates were labeled with 32p-ATP, a single band at 180 kD was 
immunoprecipitated. The incorporation of 32p into the  180- 
kD protein recognized by our antibody was stimulated in the 
presence of EGF. These results demonstrated that our poly- 
clonal antibody specifically recognized rat liver EGF recep- 
tors. 
2  The apparent  molecular weights for the rat liver EGF receptor as analyzed by 
SDS PAGE are  170 kD +  155 kD and  180 kD +  165 kD under nonreducing 
and  reducing conditions,  respectively. Nonreducing  SDS PAGE is necessary 
when the receptor is identified and quantified on immunoblots. 
Figure 1.  Specificity of the anti-EGF-R antibodies (A) EGF receptor 
purified from rat liver; Coomassie Blue staining (CB) bands at  180 
and  165 kD (Reduced) or at 170 and 155 kD (Nonreduced). Labeling 
of purified receptor with  [3,-32p]ATP  in  the presence of EGF (32p) 
and  on  immunoblots with anti-EGF-R antiserum followed by  ~251- 
protein A  (IB).  (B) Liver homogenate (150-#g protein); Coomassie 
Blue staining (CB) and labeling on immunoblots with affinity-puri- 
fied  anti-EGF-R followed by  t251-protein  A  (IB) (nonreduced).  La- 
beling of solubilized liver proteins with  [~,:2P]ATP  in the  absence 
(-) or presence (+) of EGF (32p) (reduced); liver homogenate (TO- 
TAL) and anti-EGF-R IgG-Sepharose immunoprecipitates (IPPT). 
Immunolocalization  of EGF Receptors Before and 
After EGF Exposure 
Recently, we reported that EGF moved through three mor- 
phologically distinct compartments (i.e.,  Endo I, II, and III) 
enroute to lysosomes (20). 3 Biochemical evidence suggested 
that high-affinity EGF receptors were internalized with kinet- 
ics similar to those of the ligand and were present on sucrose 
gradients in  vesicles of identical density to those containing 
internalized ligand. However, the receptor appeared to escape 
lysosomal degradation,  since three times more EGF was in- 
ternalized than the number of high-affinity receptors present 
(20).  Utilizing anti-EGF-R antibodies  and  immunofluores- 
cence (Fig. 2) as well as immunoperoxidase localizations (Fig. 
3), we traced directly the pathway taken by the receptor during 
ligand uptake and degradation. 
In the absence of EGF, receptors were localized along the 
microvilli of the sinusoidal front and along the lateral surface 
of hepatocytes (Figs.  2b and  3a).  We could not detect any 
fluorescent labeling or peroxidase reaction product at the bile 
canalicular surface or inside the cell. In the presence of EGF 
and at times when ligand had not yet reached lysosomes (4 
and 15 min), there was a progressive loss of  receptors (detected 
as a  decrease in  fluorescence) at the  cell  periphery and  the 
appearance of EGF receptors in more internal regions (Fig. 
2).  At  the  electron  microscope  level,  receptors  were  first 
observed in vesicles and tubules near the sinusoidal front (Fig. 
3  We have previously classified endosomes as types I, II, and I11 based on their 
geographical locations, kinetics of ligand accumulation,  and morphology (20, 
27, 29). In accordance with the terminology of Helenius et al., we will now use 
peripheral  and internal  endosomes  (27). In hepatocytes, the  former  include 
vesicles and tubules <200-nm diameter (i.e., type 1 endosomes) located within 
1.5 um of the cell surface while the latter  include small vesicles and tubules 
<200-nm diameter  (i.e., type  II endosomes)  and  MVEs >200-rim  diameter 
(i.e., multivesicular bodies or type III endosomes) located in the Golgi/lysosome 
region of the cell. 
The Journal of Cell Biology, Volume 102, 1986  26 Figure 2.  Immunofluorescence localization of EGF receptors in livers before and after exposure to EGF. Livers were either perfused fixed in 
situ (a and b) or perfused at 4"C in the presence of EGF, warmed to 37°C  for 4 rain (c) or 15 min (d), and then fixed. 0.5-ttm sections were 
then incubated with affinity-purified anti-EGF-R lgG followed by rhodaminated goat anti-rabbit IgG as described in Materials and Methods. 
(a and b) Before EGF exposure, fluorescence (b) was localized at the sinusoidal and lateral surfaces of hepatocytes. No labeling was observed 
at bile canaliculi (arrowheads) or within the cell. (a) Corresponding phase contrast micrograph. (c and d) EGF internalization resulted in a 
progressive loss of cell surface labeling that coincided with the intracellular accumulation of fluorescence in small discrete areas near the nucleus 
(N). SL, sinusoidal lumen. Bar,  10 #m. 
3 b). These receptor-positive structures resembled coated ves- 
icles and peripheral endosomes (20).  Between 4 and  15 min 
after EGF internalization,  the  number of receptor-positive 
vesicles near bile canaliculi increased. These vesicles (Fig.  3, 
c and  d)  were morphologically identical to the  lipoprotein- 
containing vesicles or multivesicular structures (i.e.,  multive- 
sicular endosomes, MVE) that contained EGF conjugated to 
horseradish peroxidase (EGF-HRP) (Fig. 3 e). Smaller vesicles 
and tubules near the bile canaliculus that contained internal- 
ized ligand (EGF-HRP) were receptor-negative (compare Fig. 
3, c and d to 3 e). 
Effects of  EGF on the Turnover of  EGF Receptor in 
the Perfused Rat Liver 
In an earlier study,  we reported that  the  number of ligand 
molecules internalized and degraded by hepatocytes exceeded 
the total  number of functional  receptors in  these cells.  We 
postulated  that  either  receptors  were  recycled  or  inactive 
receptors were recruited.  To establish whether receptors es- 
caped degradation and thus were available for re-utilization, 
we  quantified  the  amount  of receptor  protein  and  EGF- 
binding activity present in cell homogenates at various times 
27  Dunn et al. Epidermal Growth Factor Receptor in Liver Figure 3.  lmmunoperoxidase  localization of EGF receptors in livers before and after exposure to EGF (a-d) and visualization of ligand- 
positive vesicles by EGF-HRP cytochemistry (e). Naive livers obtained from untreated rats (a) and isolated livers perfused in the presence of 
EGF for 15 min (b-d) were fixed, frozen, sectioned, and incubated with affinity-purified anti-EGF-R IgG followed by sheep anti-rabbit Fab 
conjugated to horseradish peroxidase as described in Materials and Methods. (a) In the absence of EGF, the receptor was distributed along 
both the sinusoidal (SF) and lateral (LS) surfaces of hepatocytes. (b-d) By 15 min, the receptor was located in vesicles at the cell periphery 
and near the Golgi/lysosome region of the cell. At the periphery, receptor was visualized in structures resembling coated pits and vesicles  (small 
arrowheads) and in larger vesicles (arrows), while in more internal regions, receptor-positive multivesicular endosomes (MVE) were observed. 
(e) An isolated perfused liver at 37"C was exposed to EGF-HRP for 10 min and the ligand-containing vesicles identified, by the presence of 
peroxidase reaction product, as previously described (20). MVEs containing EGF were morphologically identical to receptor-positive vesicles. 
However, the  numerous smaller vesicles and tubules that contained ligand (arrowheads) were receptor-negative. Ly,  lysosome; Go~ Golgi 
apparatus. Bar, 0.5 urn. 
after exposure of perfused livers to EGF. 
Livers were perfused in the  presence or absence of EGF 
under conditions that  inhibited protein  synthesis (i.e.,  0.5 
mM cycloheximide) (32), and the amount of EGF receptor 
present in homogenates prepared from biopsies taken at se- 
lected times was quantified on immunoblots. A representative 
autoradiogram is presented in Fig. 4A. Addition of EGF to 
the perfused rat liver resulted in a rapid loss of receptor protein 
and a decrease in its half-life from 8.7 to 2.5 h (Table I). The 
half-life of EGF-binding  activity also decreased from  I 1.2 to 
4.5 h upon ligand exposure. However, the loss of high-affinity 
EGF-binding  sites was not coincident with EGF degradation. 
In fact,  more ligand was degraded  in 8  h  than  number of 
high-affinity binding sites lost (Table I). 
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EGF and Its Receptor 
The results described above demonstrated that EGF increased 
the rate of disappearance of receptor protein. Since  we had 
previously shown that ligand was degraded within lysosomes 
(20),  we  next determined whether the EGF-induced loss of 
receptors  was  also  affected  by  inhibitors  of the  lysosomal 
pathway (17,  18). EGF was added to livers  perfused under 
conditions that inhibited fusion of endosomes with lysosomes 
Figure 4.  The effects of EGF (A) and  lysosomal inhibitors (B) on 
the  loss of receptor protein  in  rat  liver  homogenates.  Livers were 
perfused with (A) medium containing 0.5 mM cycloheximide in the 
absence (-) or presence (+) of EGF or (B) EGF at 37"C (CONT), at 
16°C, or at 37"C in the presence of 0.4 mM leupeptin (LEUP). At 
the indicated times, biopsies were excised, homogenates prepared, 
and the relative amounts of receptor protein visualized on immuno- 
blots as described in Materials and Methods. 
Table L  Effects of  EGF on Receptor Turnover* 
(16°C) or lysosomal proteolysis (37°C plus leupeptin) and the 
dynamics of both ligand and receptor were followed (Table II 
and Figs. 4B and 5). 
At  16"C, internalization  of EGF was limited to amounts 
equivalent  to  the  number  of initial  high-affinity  receptors 
measurable in vitro (Table  II). In addition, EGF degradation 
was  completely inhibited,  and the  reduction  of hepatocyte 
receptor protein that was seen  upon EGF exposure at 37"C 
was not evident at this low temperature (Table II and Fig. 
4B).  When  the subcellular distribution  of sequestered  1251- 
EGF from livers perfused at  16"C was examined,  18% of the 
homogenate radioactivity sedimented with the lysosome-rich 
12K  pellet  and  74%  with  the  microsomal  pellet.  Sucrose 
gradient analysis of the latter fraction indicated that >75% of 
the 125I-EGF  was in low density vesicles (Fig. 5). Morpholog- 
ical examination of livers exposed to the cytochemical tracer 
EGF-HRP at  16"C confirmed that the ligand was present in 
endosomes,  both  peripheral  and  internal  tubular  elements 
(morphology not  shown).  Next,  high-affinity  EGF binding 
sites were measured in gradient fractions from a liver perfused 
with EGF at  16"C for 2 h. These receptors were lost from an 
accessible  pool at the plasma membrane and quantitatively 
recovered as  a  latent  pool  in  vesicles  that  equilibrated  on 
sucrose  gradients at densities  identical  to ligand-containing 
vesicles (Fig. 5). We reported a similar redistribution of EGF 
receptors upon addition of ligand to perfused liver at 37"C for 
10-15 m (Figs. 9 and 10 in reference 20). Immunoperoxidase 
cytochemistry on  16"C livers  revealed  that the receptor was 
present in endosomes that were structurally identical  to those 
containing EGF-HRP (morphology not shown). 
When the effects of leupeptin on ligand  and receptor dy- 
namics were examined, we found that this inhibitor had no 
effect on EGF uptake but inhibited the release of acid-soluble 
radioactivity by  as  much  as  80%  (Table  II).  As  a  result, 
460,000  molecules of EGF  accumulated  in  the  leupeptin- 
treated hepatocyte, as compared with 200,000 molecules in 
the untreated cell at steady state. In addition, leupeptin com- 
pletely  blocked the  ligand-induced loss  of receptor protein 
(Fig. 4 B). We have previously reported that EGF accumulated 
High-affinity receptors (molecules/cell) 
-EGF  +EGF 
Total receptor protein (%)  Excess ligand 
-EGF  +EGF  Ligand degraded  processed* 
mo~u~/c~ 
Time (h) 
0  340,000  340,000  100  100 
1  320,000  58  180,000  + 160,000 
2  230,000  44  320,000  +210,000 
3  165,000  34  640,000  +465,000 
4  255,000  160,000  72  27  650,000  +470,000 
6  250,000  140,000  71  18  780,000  +580,000 
8  200,000  100,000  50  17  990,000  +750,000 
Half-time  1 1.2 h  4.5 h  8.7 h  2.5 h 
* Livers were perfused in the absence and presence of 20 nM EGF at 37"C with medium containing 0.2 mM cycloheximide. At selected times, 0.3 g biopsies were 
excised, homogenized,  and the number of high-affinity receptors and the relative amounts of receptor  protein  determined  by EGF binding  and immunoblot 
analysis, respectively, as described in Materials'and  Methods. Any potential problems introduced by the presence of sequestered EGF were eliminated by the assay 
conditions.  This was accomplished using t251-EGF of 10-fold higher specific activity and at an amount that exceeded that of the sequestered ligand by a factor of 
ten.  In addition,  75%  of the sequestered  EGF was released in the presence of Brij 35,  thereby exposing latent  receptors. The amount of ligand degraded was 
quantified  as described in Materials and Methods. Values presented for 1 h and 8 h were a single determination  while the remaining values were averages of 2-4 
measurements. 
t The amount of ligand degraded in excess of the number of high-affinity receptors lost over a given time period (e.g., t =  1 h-8 h) was calculated as follows: ligand 
degraded at time t -  (340,000 -  high-affinity receptors remaining at time t). 
29  Dunn et al. Epidermal Growth Factor  Receptor in Liver Table H.  Effects of Temperature and Leupeptin on the Uptake and Degradation of'z~I-EGF in the Perfused Liver* 
Rates of Ligand Uptake  Amount of 
Rate of degradation  Amount of  ligand 
Experiment  Primary (0-15 m)  Secondary (30-240 m)  (30-240 m)  ligand internalized  degraded 
molecules/minperceg  molecules/4hpercell 
37°C  20,000  2,500  2,500  890,000  690,000  * 
16°C  17,000  0  0  260,000  0 
Leupeptin  23,000  1,700  480  770,000  310,000  § 
* '2~I-EGF (20 nM) was perfused through isolated  livers at  16°C or at 37"C in the absence  or presence of leupeptin  (0.4  nM) and the rates and extents  of ligand 
uptake and degradation  determined from the amounts of acid-soluble  and insoluble radioactivity  in the medium and liver. The primary and secondary  rates of 
EGF uptake were calculated from the rate of disappearance of acid-insoluble radioactivity from the perfusate between 0-15 min and 30-240 min, respectively. The 
rate of degradation was defined as the rate of accumulation of acid-soluble radioactivity in the perfusate of which 80% was free '2~I. The values represent an average 
of at least three experiments. 
20% of the total acid-soluble radioactivity,  or the equivalent of 138,000  molecules of '2~I-EGF per cell, were recovered in untreated livers and presumed to be 
partially degraded ligand. 
60% of the total acid-soluble radioactivity,  or the equivalent of 186,000 molecules of 'z~I-EGF per cell, was recovered in leupeptin-treated livers and presumed to 
be partially degraded ligand. 
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Figure 5.  Distribution on sucrose gradients of sequestered EGF and 
of EGF  re "eptors in  the  microsomal fraction obtained  from livers 
perfused at 16"C with EGF. Microsomal fractions were prepared from 
homogenates  obtained  from  naive  livers (CONT) or  from  livers 
perfused at  16°C with 20 nM '251-EGF for 2  h (EXPT) as previously 
described  (20).  Portions were then subfractionated on  linear  1.06- 
1.20 g/cc  sucrose gradients and EGF-binding activities measured as 
described in Materials and Methods. Arrows mark the peak activities 
for the plasma membrane (PM) marker, alkaline phosphodiesterase. 
in  the  lysosomes of  leupeptin-treated  livers  (20).  If  EGF 
receptors were also degraded  in  lysosomes, leupeptin  treat- 
ment should lead to their accumulation in these structures. 
To examine this, we perfused EGF through the liver in the 
presence of leupeptin for 2 h and then compared the cellular 
distribution of receptors by  immunofluorescence to that of 
lysosomes revealed by acid phosphatase histochemistry (Fig. 
6). There was a large degree of coincidence of the two patterns, 
suggesting that receptors were in lysosomes. At the ultrastruc- 
tural level, immunoperoxidase reaction product was found in 
MVEs and in large autophagic vacuoles, the latter of which 
were  acid-phosphatase  positive  (Fig.  6).  All  of our  results 
suggest that EGF-induced receptor loss was due to lysosomal 
degradation. 
Two Distinct Pools of  EGF Receptors 
The perfused liver internalized and degraded ligand well in 
excess of total high-affinity receptors (990,000  molecules of 
EGF degraded versus 340,000 EGF-binding sites/hepatocyte), 
even  in the presence of cycloheximide (Table  I).  Since en- 
hanced receptor degradation occurred under these conditions, 
it  was  unlikely  that  receptor  re-utilization could  alone  be 
responsible for the continued uptake of EGF. Therefore, we 
utilized an immunological approach to explore the possibility 
that the hepatocyte contained more than the 300,000-340,000 
high-affinity  receptors measured at  80  nM  EGF  in  our in 
vitro binding assay. 
We had shown that high-affinity EGF-binding  activity in 
naive livers co-migrated on  sucrose gradients with conven- 
tional plasma membrane markers (Fig. 5). However, we found 
the distribution of receptor protein (155  kD +  170  kD) on 
sucrose gradients of subcellular fractions to be different (Fig. 
7).  70%  of the high-affinity  EGF-binding  activity found in 
both the 12K and 100K fractions equilibrated in vesicles with 
densities  of  1.14-1.17  g/cc,  which  was  coincident  with  a 
membrane glycoprotein (CE 9) recently shown to be exclu- 
sively  in  the  sinusoidal  and  lateral  surfaces of hepatocytes 
(30). In contrast, vesicles containing protein that reacted with 
our anti-EGF-R  antibody distributed  in  2-3  regions of the 
sucrose gradients. Less than 50% of the total immunoreactive 
protein recovered from either the 12K or 100K gradient was 
in vesicles that equilibrated with plasma membranes on su- 
crose gradients. Of the total immunoreactive protein present 
in the  12K  fraction, 23%  equilibrated  at densities of  1.08- 
1.12  g/cc  and  15%  at  1.18-1.21  g/cc,  and  in  the  100K 
fraction,  45%  equilibrated  at  1.08-1.12  g/cc.  A  5-10-fold 
higher ratio of receptor protein-to-binding activity (i.e., lower 
specific activity) was detected at densities  1.08-1.12  g/cc as 
compared  with  that  found  at  1.14-1.17  g/cc  (i.e.,  plasma 
membrane). 
Our inability to measure EGF binding in the lower density 
The Journal of Cell Biology, Volume 102. 1986  30 Figure 6.  Visualization of EGF receptors in acid phosphatase-positive  structures. Livers were continuously perfused with 20 nM EGF and 0.4 
mM leupeptin  for 2 h. For light microscopy (left panels), 0.5-um sections were first incubated with CMP for I0 rain at 37"C and the reaction 
product visualized with PbNO3 and NaS2, These sections were then incubated with first and second antibodies as described in Fig. 2. A majority 
of the fluorescent pattern  co-localized with the acid phosphatase  precipitate (arrowheads). N, nucleus; SL, sinusoidal lumen.  Bar, 10 ~m. At 
the ultrastructural  level (right panels), individual livers were processed for immunoperoxidase  labeling (EGF-R)  as described in Fig. 3 or for 
acid phosphatase  cytochemistry (APase) as described in Materials and Methods. EGF receptors were present in MVEs (arrows) and in large 
autophagic vacuoles (A V). Acid phosphatase was found predominantly  in the latter vacuoles and occasionally in multivesicular structures (not 
shown). Go, Golgi apparatus.  Bar, 0.5 ~m. 
region of the gradients could have been due to latency of the 
receptors  and  resistance  of the  vesicles  they  reside  in  to 
detergent (i.e.,  Brij  35) permeabilization,  or to the presence 
of a  receptor with low affinity for EGF. All of the receptors 
in plasma membrane vesicles were accessible to EGF (Fig. 5), 
while  -70%  of the  EGF-binding  activity  measured  in  the 
lower density  vesicles displayed  latency,  ruling out the  first 
possibility (Fig. 8). We next characterized EGF binding to the 
two types of receptors by Scatchard analysis in the presence 
of 0.3%  Brij  35 (Fig.  8).  The pool of receptors at  1.14-1.17 
g/cc exhibited a single high-affinity binding site with a Ka of 
12  nM.  This  value  was  similar  to  that  measured  in  liver 
homogenates (20). A curvilinear Scatchard plot was observed 
for the receptors present at 1.08-1.12 g/cc with a majority of 
these receptors expressing a lower affinity (Ka -  200 nM) for 
EGF. These results demonstrated the existence of two pools 
of receptors in hepatocytes having different affinities for EGF 
and residing in two biochemically distinct vesicles. 
Comparison of  EGF-Binding and Receptor Protein 
Kinase Activities with Immunoreactivity 
Human EGF receptor contains a ligand binding domain and 
a  protein  kinase domain that are separated  by a  transmem- 
brane region of 23 amino acids (55). We showed that the EGF 
receptor purified or immunoprecipitated from liver homoge- 
nates had the expected protein kinase activity. Having iden- 
tified two pools of receptors with different affinities for EGF, 
we  next  compared  the  protein  kinase  activities  of the  two 
receptor forms as  measured  by autophosphorylation.  Low- 
and  high-affinity receptors were solubilized  in 0.5%  Triton 
X-100 from their respective regions of the sucrose gradients 
and incubated with [~,-32P]ATP in the absence and presence 
of EGF. The results presented in Fig. 9 show that both forms 
of the  receptor exhibited  EGF-dependent  autophosphoryla- 
tion. Phosphorylation of receptors solubilized from either the 
1.08-1.12  g/cc  or  1.14-1.17  g/cc  density  regions  was  en- 
hanced 5-10-fold by ligand. An EGF concentration of 300- 
400 nM was necessary for half maximal stimulation of both 
receptors, with maximal phosphorylation occurring at 4 zM 
EGF.  The amount of 32p incorporated was proportional to 
the  amount  of receptor  protein  present  as  quantified  on 
immunoblots.  These  results  demonstrated  that  under  our 
assay conditions, both low- and high-affinity receptors bound 
EGF and had similar levels of EGF-stimulated protein kinase 
activity after solubilization in Triton X-100. 
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Figure 7.  Distribution of EGF-binding activity and receptor protein 
on sucrose gradients of the 12K and 100K pellets. Naive livers were 
perfused with ice-cold saline and homogenized. 12K and 100K frac- 
tions were prepared and portions subfractionated on 1.10-1.25  g/cc 
sucrose gradients.  Total high-affinity EGF-binding activity was mea- 
sured in the presence  of Brij 35  (O), and the amounts of receptor 
protein (0) and CE 9 antigen (A) were quantified on immunoblots 
as described in Materials and Methods. Arrows mark the peak activ- 
ities for alkaline phosphodiesterase (plasma membrane, PM) and ¢/- 
N-acetylglucosaminidase  (lysosomes, L YS). 
Biochemical Comparison  of the Two Receptor Forms 
Since the low- and high-affinity forms of the EGF receptor 
could  be  segregated on  sucrose gradients,  we  were  able to 
compare several of their biochemical characteristics. 
The fact that our antibody recognized both receptor forms 
suggested that  there  was  some  homology  in  their  peptide 
structures.  To  further evaluate the extent of homology, we 
subjected both receptor forms to peptide map analysis. Tryptic 
(Fig. 10A ) and chymotryptic (not shown) digests of the mol- 
ecules immunoprecipitated  from  the  two  different  vesicles 
yielded identical peptide maps. Thus,  no  major differences 
could be detected. 
The apparent molecular weight and amount of the cryptic 
receptors suggested that they were not biosynthetic precursor 
forms. Nonetheless, we examined this possibility  by determin- 
ing whether sialic acid residues were present, as evidence for 
presence of complex oligosaccharides on the cryptic receptors. 
Equal amounts of immunoprecipitated receptor as quantified 
on immunoblots were resolved by SDS PAGE, transferred to 
nitrocellulose, and subsequently labeled with ~25I-WGA using 
an enhancement method recently reported by our laboratory 
(4).  WGA  labeled both  forms  of the  receptor to  a  similar 
extent  and  the  labeling was  completely inhibited by  prior 
treatment with neuraminidase (Fig. 10B). 
Discussion 
In a  previous paper, we showed that both ligand and high- 
affinity EGF-binding sites were  internalized into  endocytic 
vesicles upon exposure of hepatocytes to EGF. EGF was then 
degraded within lysosomes, but at a rate faster than the loss 
of high-affinity receptors.  At  that  time,  we  proposed that 
either EGF receptors escaped lysosomal degradation and were 
re-utilized or that additional inactive receptors were recruited 
for further  rounds  of ligand internalization. In the  present 
study, we utilized polyclonal antibodies prepared against rat 
liver receptor to  examine  these  two  possibilities. We  have 
found that the EGF receptor protein is degraded more rapidly 
as a  consequence of exposure to EGF, that it is degraded in 
lysosomes, and  that  continued uptake  of ligand is not due 
entirely to receptor recycling. In addition, we have identified 
in the hepatocyte a  pool of -300,000  low-affinity receptors 
that may account for the continued uptake of EGF. 
Fate of the Receptor after Exposure  of Cells to EGF 
Krupp et al. (34), Stoscheck and Carpenter (52), and Beguinot 
et ai. (6) have shown that receptor degradation was enhanced 
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Figure 8.  Scatchard plot representation of EGF-binding in sucrose 
gradient fractions.  Sucrose  gradient fractions 5-8 and  11-16  were 
pooled (see Fig. 7). Aliquots were then incubated with 5-500 nM 125I- 
EGF in the absence (open symbols) or in the presence (closed sym- 
bols) of 0.3% Brij 35 and the amount of EGF-binding determined as 
described in  Materials and  Methods.  The  straight  line plots and 
resulting Kd values were derived by linear regression analyses. 
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ATP labeling in the absence and 
presence of EGF of the low and 
high affinity forms of the  EGF 
receptor. EGF receptors were sol- 
ubilized in  0.5% Triton  X-100 
from  the  1.08-1.12 g/cc  (frac- 
tions  5-8) and  1.14-i.17  g/cc 
(fractions 11-16) regions of the 
100K gradient (see Fig. 7) and 
incubated in a final volume of  50 
tzl in the absence and presence of 
4 uM EGF at 4"C for 60 min. [~- 
32p]ATP was then  added  for 4 
min at 4"C and the reaction ter- 
minated by the addition of un- 
labeled ATP (2 mM), inorganic 
pyrophosphate (20 mM), sodium 
vanadate  (0.01  mM),  and  so- 
dium  fluoride  (200 mM).  The 
32p-labeled  EGF  receptor  was 
then  immunoprecipitated,  solu- 
bilized in SDS and dithiothreitol 
at 100*C for 3 rain, and analyzed 
by SDS PAGE and autoradiog- 
raphy. 
when A431  cells,  human foreskin fibroblasts, and  KB cells 
were exposed to EGF. We have observed similar results when 
EGF  was  perfused  through  an  isolated  liver.  It  has  been 
suggested that  receptors are degraded  along with  ligand  by 
lysosomal proteinases, but the published evidence is not de- 
finitive. Based on the finding that receptor degradation was 
inhibited when cells were exposed to the weak bases, meth- 
ylamine and chloroquine, several investigators have proposed 
that  degradation  occurred  within  lysosomes  (14,  52).  Al- 
though these amines elevate lysosomal pH, they also affect 
pre-lysosomal events by altering endosomal pH (37).  It has 
been reported that NH4C1 prevents the transfer of asialogly- 
coproteins (26)  and  EGF (39)  into  lysosomes. In  KB cells 
previously treated with EGF, Beguinot et al. have traced the 
movement of EGF receptors from the cell surface to structures 
they identified as lysosomes based on morphological criteria 
(6).  Again,  the  presence of receptors in  acid  phosphatase- 
positive vesicles was not demonstrated. 
In this paper, we have presented morphological and bio- 
chemical evidence suggesting that the ligand-induced loss of 
hepatocyte EGF receptors was due to hydrolysis in lysosomes. 
Within  15 min of EGF internalization, we found receptors in 
MVEs.  Wall et al.  have reported that structures containing 
lactosaminated ferritin and resembling MVEs could be nega- 
tive  or  positive  for  aryl-sulfatase  activity,  suggesting  that 
MVEs were immediate precursors to lysosomes (56).  Geuze 
et al. proposed that ASGP receptors were recycled via small 
tubules while ASGP-containing MVEs fused with lysosomes 
(24).  Thus, the detection of EGF receptors in MVEs is con- 
sistent  with,  but  not  definitive  of,  lysosomal degradation. 
Therefore, we investigated the effects of specific inhibitors of 
the lysosomal pathway on the EGF-induced loss of receptors. 
These inhibitors  included  low temperature (<20"C),  which 
prevents  endosome/lysosome  fusion  (18),  and  leupeptin, 
which inhibits lysosomal cathepsins B, H, and L (3), yet has 
no effect on ligand entry into lysosomes (17,  20).  Both con- 
ditions inhibited EGF-induced loss of  receptors, and leupeptin 
resulted in demonstrable accumulation of intact EGF recep- 
tors in acid-phosphatase structures. All of  these results provide 
strong evidence that ligand and receptor are transported along 
the same pathway to lysosomes. However, from these results 
we cannot conclude that every receptor that bound ligand at 
the cell surface was transported to lysosomes and immediately 
degraded. It is possible that some fraction of the receptors was 
recycled. 
Proteinase inhibitors and lysosomotropic agents have been 
used to  identify the  site(s)  of degradation of other integral 
plasma membrane proteins. Leupeptin and chloroquine had 
no effect on the steady-state turnover of insulin receptors in 
chick liver cells (33) but efficiently inhibited the degradation 
ofacetylcholine receptors in cultured muscle cells (35). These 
results suggest that at least two different degradative pathways 
(i.e.,  nonlysosomal and lysosomal) exist for the turnover of 
plasma membrane proteins. In addition, it is interesting that 
EGF receptors are  apparently not  re-utilized but  degraded 
within lysosomes, while insulin receptors are re-utilized (22) 
and degraded by a nonlysosomal mechanism. Further exper- 
iments will  be necessary to substantiate this interesting cor- 
relation. 
The  dissociation  of receptor  and  ligand  within  an  acid 
environment has been related to receptor recycling. That is, 
for  those  ligand-receptor  complexes that  dissociate  under 
acidic conditions, the receptor apparently escapes lysosomal 
degradation  and  is  re-utilized  (8).  Consistent  with  such  a 
mechanism is the behavior of human choriogonadotropin- 
receptor complexes, which are stable at pH -4 and have been 
shown  to  enter  lysosomes where  ligand  and  receptor  are 
degraded (1). EGF dissociates from its receptor at pH 5.0 (20), 
the approximate pH measured for endosomes (37,  54).  Yet 
EGF receptors, apparently unoccupied, are transported along 
with ligand to lysosomes. Since a  majority of the  receptors 
are degraded, it is not presently clear why the complex is acid- 
sensitive or what signals direct unoccupied receptors to lyso- 
somes.  However, our observations on  the  behavior of this 
receptor raise the possibility that dissociation of ligand from 
receptor  may  not  be  the  only signal  involved in  receptor 
recycling. 
Two Distinct Receptor Pools 
When EGF binding in liver homogenates was initially exam- 
ined,  ~300,000  high-affinity sites of Kd 8-15  nM  were de- 
tected (20).  In this paper we have identified low- and high- 
affinity receptors, both of which have protein kinase activity 
and are structurally similar. Is it possible that low-affinity sites 
could have arisen from our homogenization conditions? We 
believe this  to  be unlikely for the  following reasons.  First, 
discrete vesicles that could be separated on equilibrium gra- 
dients  contained  either  only  high-  or  predominantly  low- 
affinity  receptors,  not  variable  mixtures.  Second,  we  have 
observed an equal distribution  of receptor protein between 
these  two  pools  in  six  experiments,  our  estimate  being 
-300,000  in  each.  4 Third,  when  EGF (20 nM)  is perfused 
through a liver at 16"C, ligand internalization is limited to the 
number of high-affinity receptors we can  measure in  vitro 
4 The -300,000 high-affinity receptors assayed in liver homogenates appear to 
be at the cell surface, because they are accessible  to EGF in vitro and co-migrate 
on sucrose gradients with plasma membrane  markers, lmmunoblot analysis 
indicates that there is an equal number or ~300,000 receptors/cell residing in 
low density vesicles. 
33  Dunn et al. Epidermal Growth Factor Receptor in Liver Figure 10.  Comparison  of the tryptic peptide maps (A) and wheat germ agglutinin labeling (B) of the low and high affinity forms of the EGF 
receptor. EGF receptors were immunoprecipitated  from the 1.08-1.12 g/cc (fractions 5-8) and 1.14-1.17 g/cc (fractions 11-16) regions of the 
100K sucrose gradient (see Fig. 7), solubilized, and electrophoresed in polyacrylamide gels. (A) Coomassie Blue bands corresponding to the 
180-kD polypeptides in each immunoprecipitate  were iodinated, digested with trypsin, and the resulting peptides separated according to the 
procedure  of Elder et al. (21). (B) Proteins were transferred  from the polyacrylamide gel to nitrocellulose, and ~251-WGA  labeling was done 
either immediately or after treatment with 0.01 U neuraminidase  (NANADASE) at 37"C for 4 h. 
(Table II). In addition, at  16"C the plasma membrane pool of 
EGF binding sites is depleted, with an equivalent number of 
latent,  high-affinity binding sites appearing in endosomes in 
the density range of 1.08-1.12 g/cc (Fig. 5). These two results 
from 16"C experiments suggest that only ~300,000 receptors 
are  available  to  bind  and  internalize  the  ligand  and  that 
neither receptor internalization nor our homogenization con- 
ditions alter the EGF binding properties of the high affinity 
receptor. Fourth, the rapid phase of EGF uptake observed at 
37°C results in the internalization of not more than 300,000 
ligand  molecules  and  can  be  mediated  by  only  the  high- 
affinity receptors present  at  the cell  surface,  since the EGF 
concentrations in the perfusion medium are 20 nM? Thus, 
many lines of evidence suggest that there are only ~300,000 
high-affinity binding  sites  per hepatocyte,  not  -600,000  as 
there would be if the low-affinity sites were an artifact of our 
homogenization conditions. 
The cryptic receptor we have identified  expressed  a  very 
low but  measurable  affinity for EGF and exhibits  an  EGF- 
dependent protein kinase activity. It is possible that our assay 
conditions (e.g.,  0.3%  Brij  35) may have reduced this recep- 
tor's  affinity.  However,  identical  assay  conditions  had  no 
effect on the affinity of receptors that were internalized after 
addition of EGF to the perfused liver at either 37°C (20) or at 
16"C (Fig. 5). Therefore, the additional cryptic receptors are 
either structurally different or reside  in a  different environ- 
ment  from the  high-affinity receptors  found at  the  plasma 
membrane  or those internalized  into endosomes after  EGF 
exposure. Regarding the first possibility, we have not observed 
any major structural differences. Unlike the insulin and nerve 
growth factor receptors (10,  13), we have not detected oligo- 
meric forms of the EGF receptor. Both low- and high-affinity 
forms have the same apparent molecular weights of 180 kD 
and  170  kD  under  reducing  and  nonreducing  conditions, 
s The EGF concentration necessary  for half-saturation of  ligand binding  at 4"C 
in the perfused liver was -2 nM and in liver homogenates  8-15 nM (20). 
respectively,  and  are  structurally  related  as  determined  by 
tryptic peptide maps. Furthermore, although the acquisition 
of EGF binding occurs late in the biosynthetic pathway of the 
receptor and apparently requires posttranslational  glycosyla- 
tion (48,  49),  both  low- and  high-affinity receptors contain 
sialic acid-terminating  oligosaccharide chains.  It is possible 
that phosphorylation may account for the affinity differences. 
12-O-Tetradecanoylphorbol-13-myristate has  been  reported 
to stimulate the phosphorylation of receptor threonine resi- 
dues  (l 5,  31)  and  to  inhibit  high  affinity  EGF  binding  in 
human  cells  (23,  47).  Alternatively,  environmental  factors 
may alter the receptor's conformational state and thereby its 
ability  to  bind  EGF.  For  example,  DiPaola  and  Maxfield 
reported that under acidic conditions the receptor undergoes 
a  conformational change within  the membrane bilayer that 
may reflect the  receptor's inability to bind  EGF at  pH  5.6 
(16). It is also possible that receptor affinity has been altered 
by interaction of the protein with other membrane proteins, 
lipids,  and/or  cytoskeletal  proteins  as  was reported  for the 
nerve growth factor receptor (10, 45). 
The cellular location of the pool of cryptic receptors is not 
clear at this time.  Low-affinity EGF receptors are found in a 
membrane-bounded  compartment  that  co-migrates  on  su- 
crose gradients with  Golgi  elements and endocytic vesicles. 
However, receptors in naive livers have been localized almost 
exclusively to the cell surface by immunolabeling techniques 
(Fig. 2). This apparent discrepancy has not been resolved, but 
one possibility is  that  our antibody does  not  recognize the 
cryptic  pool  in  fixed  tissue  due  to  its  orientation  in  the 
membrane or its altered conformational state. A second pos- 
sibility, that homogenization procedures may have broken or 
ruptured the plasma membrane into microdomains that were 
then  separated on sucrose gradients,  seems unlikely for two 
reasons. First, CE 9, a membrane protein present exclusively 
in  the  sinusoidal/lateral  plasma  membrane  of hepatocytes, 
did  not exhibit  a  bimodal distribution  when  either a  100K 
(Fig. 1) or a purified plasma membrane (see Fig. 2 in reference 
The Journal of  Cell Biology.  Volume 102, 1986  34 5) fraction was subfractionated on sucrose gradients. Second, 
the  distribution  of  EGF  receptor  in  sucrose  gradients  of 
plasma membrane subfractions coincided with that of CE 9 
(i.e., a single peak at 1.13-1.15 g/cc) (data not shown). 
Dynamics of  Low- and High-Affinity Receptors 
We do not have direct evidence that the low-affinity receptor 
functions in endocytosis nor do we know its precise relation- 
ship to the high-affinity  form. The absence of high-affinity 
receptors in endosomes strongly suggests that EGF endocy- 
tosis is not occurring in freshly isolated livers. Therefore, it is 
unlikely that the cryptic receptors are a recycling pool induced 
by EGF internalization. However, we suggest from the follow- 
ing observations that the low-affinity receptors are responsive 
to EGF and may account for the continued uptake of ligand. 
The cryptic low-affinity receptor accounts for at least 50% of 
the total receptor protein (-600,000  receptors/hepatocyte).  4 
In the presence of EGF as much as 90%  of the total receptor 
protein is lost, suggesting that ligand enhances the degradation 
of receptor in both pools. The simplest hypothesis (although 
certainly not the only one) is that the low-affinity receptors 
must be inserted into the plasma membrane where they then 
bind and internalize more ligand. However, the concentration 
of EGF in the perfusing medium (20 nM) is well below the 
Kd of the low-affinity receptors, necessitating activation of the 
receptors for them to bind ligand. This series of events appears 
to be  inhibited  at  low temperatures but  is  not affected  by 
leupeptin inhibition of proteolysis. That is, EGF internaliza- 
tion at  16"C is limited to amounts equivalent to the number 
of high-affinity receptors measured in vitro (300,000  recep- 
tors/hepatocyte).  However,  in  the  presence  of  leupeptin, 
>300,000  EGF molecules are taken up. Whether or not the 
movement of the cryptic receptors to the plasma membrane 
is in response to EGF is not known. It is possible, and only 
speculative at present, that in naive livers there is a recycling 
of receptors between the two pools similar to that character- 
ized for the Fc receptor in macrophages (38). However, in the 
case of the EGF receptors, there is also an interconversion of 
the two receptor forms (high- to low-affinity and vice versa). 
Upon the addition  of EGF,  this equilibrium  is altered and 
high-affinity receptors are diverted to lysosomes. Since -90% 
of all  EGF  receptors are lost after 8  h  of continuous EGF 
exposure, the ultimate fate of the receptor in the presence of 
ligand  is  lysosomal  degradation.  Nevertheless,  our  current 
estimate of ~600,000  total receptors per hepatocyte  4 is lower 
than the almost  l  x  10  6 molecules of EGF degraded in 8 h, 
suggesting that receptor re-utilization may be occurring. 
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